Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nisoldipine
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker used primarily for the management of hypertension. It acts by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance. This mechanism decreases systemic blood pressure and myocardial oxygen demand while increasing oxygen delivery to cardiac tissue. Nisoldipine is more potent as a vasodilator than nifedipine and can be used alone or in combination with other antihypertensive agents such as ACE inhibitors, diuretics, or beta-blockers. Off-label, it may be used for ischemic heart conditions like stable angina and Prinzmetal angina[1][2][3][5][6].
- Brand names
- Sular
- Other names
- nisoldipine controlled-release
02
Targets
LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on nisoldipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nisoldipine.